Amenorrhea: A Practical Approach to Diagnosis and Management

David A. Klein, MD, MPH
Jillian E. Sylvester, MD
Scott L. Paradise, MD

American Family Physician. 2026;114(1):72-85.

Author disclosure: No relevant financial relationships

This clinical content conforms to AAFP criteria for CME.

Menstrual patterns can indicate overall health and reflect changes in endocrine, metabolic, or other systemic functions. Primary amenorrhea, defined as the lifelong absence of menses, warrants evaluation by age 15 years or 3 years postthelarche. Secondary amenorrhea is defined as the cessation of previously regular menses for 3 months or irregular menses for 6 months. Evaluation begins with a focused medical history, including prior menstrual patterns; eating and exercise habits; psychosocial stressors; medication use; chronic illness; and neurologic, vasomotor, or hyperandrogenic symptoms. Physical examination should assess anthropometric trends and pubertal development. Routine laboratory testing includes pregnancy testing and serum estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, and thyroid-stimulating hormone (thyrotropin) levels. Additional testing, including karyotyping, serum androgen evaluation, and pelvic or brain imaging, is individualized. Functional hypothalamic amenorrhea may indicate treatment for underlying disordered eating or low bone density. Patients with premature ovarian insufficiency benefit from hormone therapy until the average age of natural menopause. Addressing lifetime metabolic disease and endometrial cancer risk is necessary for patients with polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome).

DAVID A. KLEIN, MD, MPH, is director of the Family Medicine Residency Program at David Grant Medical Center, Travis Air Force Base, California, and a professor of family medicine and pediatrics at the Uniformed Services University of the Health Sciences, Bethesda, Maryland.

JILLIAN E. SYLVESTER, MD, is a clinical associate professor in the Department of Orthopedics at the University of North Carolina School of Medicine, Chapel Hill.

SCOTT L. PARADISE, MD, is associate program director of the Primary Care Sports Medicine Fellowship at the Naval Hospital, Camp Pendleton, California, and an assistant professor of family medicine at the Uniformed Services University of the Health Sciences, Bethesda.

Address correspondence to David A. Klein, MD, MPH, at david.a.klein26.mil@health.mil.

Author disclosure: No relevant financial relationships

  1. 1.Pitts S, DiVasta AD, Gordon CM. Evaluation and management of amenorrhea. JAMA. 2021;326(19):1962-1963.
  2. 2.Cipres DT, Gordon CM. Primary ovarian insufficiency, bone health, and other outcomes in adolescents. Obstet Gynecol Clin North Am. 2024;51(4):663-678.
  3. 3.ACOG Committee Opinion No. 651: menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Reaffirmed in 2025. Obstet Gynecol. 2015;126(6):e143-e146.
  4. 4.Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
  5. 5.Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997;99(4):505-512.
  6. 6.Eckert-Lind C, Busch AS, Petersen JH, et al. Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(4):e195881.
  7. 7.Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea: a committee opinion. Fertil Steril. 2024;122(1):52-61.
  8. 8.Klein DA, Paradise SL, Reeder RM. Amenorrhea: a systematic approach to diagnosis and management. Am Fam Physician. 2019;100(1):39-48.
  9. 9.World Health Organization Task Force on Adolescent Reproductive Health. World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. J Adolesc Health Care. 1986;7(4):236-244.
  10. 10.Brown EE, Fogleman CD. Disorders of puberty: common questions and answers. Am Fam Physician. 2025;112(5):513-521.
  11. 11.Klein DA, Poth MA. Amenorrhea: an approach to diagnosis and management. Am Fam Physician. 2013;87(11):781-788.
  12. 12.Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439.
  13. 13.Panay N, Anderson RA, Bennie A, et al.; ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065.
  14. 14.Sánchez LA, Pérez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril. 2007;87(3):712-714.
  15. 15.Facchin F, Francini F, Ravani S, et al. Psychological impact and health-related quality-of-life outcomes of Mayer-Rokitansky-Küster-Hauser syndrome: a systematic review and narrative synthesis. J Health Psychol. 2021;26(1):26-39.
  16. 16.Bortoletto P, Romanski PA, Pfeifer SM. Müllerian anomalies: presentation, diagnosis, and counseling. Obstet Gynecol. 2024;143(3):369-377.
  17. 17.Bonazza F, Politi G, Leone D, et al. Psychological factors in functional hypothalamic amenorrhea: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:981491.
  18. 18.Dobranowska K, Plińska S, Dobosz A. Dietary and lifestyle management of functional hypothalamic amenorrhea: a comprehensive review. Nutrients. 2024;16(17):2967.
  19. 19.Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023;329(16):1386-1398.
  20. 20.Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
  21. 21.Vitale SG, De Angelis MC, Della Corte L, et al. Uterine cervical stenosis: from classification to advances in management. Overcoming the obstacles to access the uterine cavity. Arch Gynecol Obstet. 2024;309(3):755-764.
  22. 22.Khan Z. Etiology, risk factors, and management of Asherman syndrome. Obstet Gynecol. 2023;142(3):543-554.
  23. 23.Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53(5):804-810.
  24. 24.Ott J, Robin G, Hager M, et al. Functional hypothalamic amenorrhoea and polycystic ovarian morphology: a narrative review about an intriguing association. Hum Reprod Update. 2025;31(1):64-79.
  25. 25.Hu S, Yu Q, Wang Y, et al. Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;297(5):1081-1088.
  26. 26.Abou Sherif S, Newman R, Haboosh S, et al. Investigating the potential of clinical and biochemical markers to differentiate between functional hypothalamic amenorrhoea and polycystic ovarian syndrome: a retrospective observational study. Clin Endocrinol (Oxf). 2021;95(4):618-627.
  27. 27.Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257.
  28. 28.Tosi F, Fiers T, Kaufman JM, et al. Implications of androgen assay accuracy in the phenotyping of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(2):610-618.
  29. 29.Gravholt CH, Andersen NH, Christin-Maitre S, et al.; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol. 2024;190(6):G53-G151.
  30. 30.Besson MDR, Taiarol MDS, Fernandes EB, et al. Chromosomal abnormalities detected by karyotyping among patients with secondary amenorrhea: a retrospective study. Sao Paulo Med J. 2023;141(5):e2022426.
  31. 31.Mountjoy M, Ackerman KE, Bailey DM, et al. 2023 International Olympic Committee's (IOC) consensus statement on relative energy deficiency in sport (REDs). Br J Sports Med. 2023;57(17):1073-1097.
  32. 32.Rarick LD, Shangold MM, Ahmed SW. Cervical mucus and serum estradiol as predictors of response to progestin challenge. Fertil Steril. 1990;54(2):353-355.
  33. 33.Mörö S, Kosola S, Holopainen E. Girls referred for amenorrhea: analysis of a patient series from a specialist center. Front Public Health. 2024;12:1304277.
  34. 34.Lopes MP, Robinson L, Stubbs B, et al. Associations between bone mineral density, body composition and amenorrhoea in females with eating disorders: a systematic review and meta-analysis. J Eat Disord. 2022;10(1):173.
  35. 35.Hornberger LL, Lane MA; Committee on Adolescence. Identification and management of eating disorders in children and adolescents. Pediatrics. 2021;147(1):e2020040279.
  36. 36.Saadedine M, Kapoor E, Shufelt C. Functional hypothalamic amenorrhea: recognition and management of a challenging diagnosis. Mayo Clin Proc. 2023;98(9):1376-1385.
  37. 37.Williams NI, De Souza MJ, Misra M, et al. 2025 update to the female athlete triad coalition consensus statement part 2: clinical guidelines for screening, diagnosis, treatment, and return to play for adolescents and adults. Sports Med. 2026;56(2):375-427.
  38. 38.Heikura IA, McCluskey WTP, Tsai MC, et al. Application of the IOC Relative Energy Deficiency in Sport (REDs) Clinical Assessment Tool version 2 (CAT2) across 200+ elite athletes. Br J Sports Med. 2024;59(1):24-35.
  39. 39.Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011;26(10):2430-2438.
  40. 40.Ackerman KE, Singhal V, Baskaran C, et al. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med. 2019;53(4):229-236.
  41. 41.Efthymiadis A, Tsikopoulos K, Mills EG, et al. Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2026;111(5):e1446-e1456.
  42. 42.Li M, Zhu Y, Wei J, et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95-102.
  43. 43.Stuenkel CA, Gompel A. Primary ovarian insufficiency. N Engl J Med. 2023;388(2):154-163.
  44. 44.Jones AR, Enticott J, Ebeling PR, et al. Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis. Hum Reprod. 2024;39(5):1013-1022.
  45. 45.Gonçalves CR, Vasconcellos AS, Rodrigues TR, et al. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Biomed Online. 2022;44(6):1143-1157.
  46. 46.Shah S, Forghani N, Durham E, et al. A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism. Int J Pediatr Endocrinol. 2014;2014(1):12.
  47. 47.Federici S, Goggi G, Quinton R, et al. New and consolidated therapeutic options for pubertal induction in hypogonadism: in-depth review of the literature. Endocr Rev. 2022;43(5):824-851.
  48. 48.Teede HJ, Khomami MB, Morman R, et al.; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339.
  49. 49.American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 194: polycystic ovary syndrome. Reaffirmed in 2025. Obstet Gynecol. 2018;131(6):e157-e171.
  50. 50.Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487-525.
  51. 51.Saleh FL, Starkman H, Furness A, et al. Polycystic ovary syndrome in adolescents. Obstet Gynecol Clin North Am. 2024;51(4):679-693.
  52. 52.Peña AS, Witchel SF. Update on diagnosis of polycystic ovary syndrome during adolescence. Fertil Steril. 2025;124(5):956-961.
  53. 53.Gautam R, Maan P, Jyoti A, et al. The role of lifestyle interventions in PCOS management: a systematic review. Nutrients. 2025;17(2):310.
  54. 54.Scragg J, Hobson A, Willis L. Effect of weight loss interventions on the symptomatic burden and biomarkers of polycystic ovary syndrome: a systematic review of randomized controlled trials. Ann Intern Med. 2024;177(12):1664-1674.
  55. 55.Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38(10):108834.
  56. 56.Beitl K, Dewailly D, Seemann R, et al. Polycystic ovary syndrome phenotype D versus functional hypothalamic amenorrhea with polycystic ovarian morphology: a retrospective study about a frequent differential diagnosis. Front Endocrinol (Lausanne). 2022;13:904706.
  57. 57.Hobbs AK, Cheng HL, Tee EYF, et al. Menstrual dysfunction in adolescents with chronic illness: a systematic review. J Pediatr Adolesc Gynecol. 2023;36(4):338-348.
  58. 58.Codner E, Merino PM, Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update. 2012;18(5):568-585.
  59. 59.Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. Am Fam Physician. 2006;73(8):1374-1382.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.